Plozasiran (ARO-APOC3)
Severe Hypertriglyceridemia
Key Facts
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals is a leader in RNAi therapeutics, driven by its mission to 'Target the Gene, Silence the Disease.' The company has achieved significant validation through its proprietary TRiM™ platform, which enables extrahepatic delivery and has generated a robust clinical pipeline, including multiple Phase 3 assets in cardiometabolic disorders. Its strategy focuses on advancing wholly-owned programs in high-need areas while selectively pursuing strategic partnerships to expand its reach and resource development.
View full company profileAbout Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals is a leader in RNAi therapeutics, driven by its mission to 'Target the Gene, Silence the Disease.' The company has achieved significant validation through its proprietary TRiM™ platform, which enables extrahepatic delivery and has generated a robust clinical pipeline, including multiple Phase 3 assets in cardiometabolic disorders. Its strategy focuses on advancing wholly-owned programs in high-need areas while selectively pursuing strategic partnerships to expand its reach and resource development.
View full company profileAbout Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals is a leader in RNAi therapeutics, driven by its mission to 'Target the Gene, Silence the Disease.' The company has achieved significant validation through its proprietary TRiM™ platform, which enables extrahepatic delivery and has generated a robust clinical pipeline, including multiple Phase 3 assets in cardiometabolic disorders. Its strategy focuses on advancing wholly-owned programs in high-need areas while selectively pursuing strategic partnerships to expand its reach and resource development.
View full company profileAbout Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals is a leader in RNAi therapeutics, driven by its mission to 'Target the Gene, Silence the Disease.' The company has achieved significant validation through its proprietary TRiM™ platform, which enables extrahepatic delivery and has generated a robust clinical pipeline, including multiple Phase 3 assets in cardiometabolic disorders. Its strategy focuses on advancing wholly-owned programs in high-need areas while selectively pursuing strategic partnerships to expand its reach and resource development.
View full company profile